Victor Mangas-Sanjuan

Dr. Victor Mangas-Sanjuan

University of Valencia (Spain)
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LGLaura García-Quintanilla
Laura García-Quintanilla
ALAndrea Luaces-Rodríguez
Andrea Luaces-Rodríguez
MGMaría Gil-Martinez
María Gil-Martinez
CMCristina Mondelo-García
Cristina Mondelo-García
OMOlalla Maroñas
Olalla Maroñas
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance.

31 March 2011 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
Hai Pham-TheHai Pham-The
Hai Pham-The
IGIsabel González‐Álvarez
Isabel González‐Álvarez
Marival BermejoMarival Bermejo
Marival Bermejo
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
ICInmaculada Centelles
Inmaculada Centelles
Miguel Angel Cabrera-PerezMiguel Angel Cabrera-Perez
Miguel Angel Cabrera-Perez

22 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MFMalgorzata Frik
Malgorzata Frik
JFJacob Fernández-Gallardo
Jacob Fernández-Gallardo
OGOscar Gonzalo
Oscar Gonzalo
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Maria ContelMaria Contel
Maria Contel
New organometallic gold(III) and platinum(II) complexes containing iminophosphorane ligands are described. Most of them are more cytotoxic to a number of human cancer cell lines than cisplatin. Cationic Pt(II) derivatives 4 and 5, which differ only in the anion, Hg2Cl62– or PF6– respectively, display almost identical IC50 values in the sub-micromolar range (25–335-fold more active than cisplatin on these cell lines). The gold compounds induced mainly caspase-independent cell death, as previously reported for related cycloaurated compounds containing IM ligands. Cycloplatinated compounds 3, 4, and 5 can also activate alternative caspase-independent mechanisms of death. However, at short incubation times cell death seems to be mainly caspase dependent, suggesting that the main mechanism of cell death for these compounds is apoptosis. Mercury-free compound 5 does not interact with plasmid (pBR322) DNA or with calf thymus DNA. Permeability studies of 5 by two different assays, in vitro Caco-2 monolayers and a rat perfusion model, have revealed a high permeability profile for this compound (comparable to that of metoprolol or caffeine) and an estimated oral fraction absorbed of 100%, which potentially makes it a good candidate for oral administration.

14 June 2022 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
Enrique Bandín-VilarEnrique Bandín-Vilar
Enrique Bandín-Vilar
LGLaura García-Quintanilla
Laura García-Quintanilla
Ana Castro BaladoAna Castro Balado
Ana Castro Balado
IZIrene Zarra-Ferro
Irene Zarra-Ferro
MGMiguel González-Barcia
Miguel González-Barcia
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro

2 July 2015 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
IGIgnacio González-García
Ignacio González-García
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
MMMatilde Merino-Sanjuán
Matilde Merino-Sanjuán
Marival BermejoMarival Bermejo
Marival Bermejo
In vitro–in vivo correlations: general concepts, methodologies and regulatory applications. . ???aop.label???.

1 August 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGuillermo Rodríguez-Berna
Guillermo Rodríguez-Berna
Victor Mangas-SanjuanVictor Mangas-Sanjuan
Victor Mangas-Sanjuan
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Isabel Gonzalez-AlvarezIsabel Gonzalez-Alvarez
Isabel Gonzalez-Alvarez
JGJosé LUIS García-Gimenez
José LUIS García-Gimenez
ACAvelino Corma
Avelino Corma